Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €51.72 EUR
Change Today +0.55 / 1.08%
Volume 226.2K
GXI On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 3:35 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

gerresheimer ag (GXI) Snapshot

Open
€51.13
Previous Close
€51.17
Day High
€52.08
Day Low
€50.93
52 Week High
09/22/14 - €56.99
52 Week Low
10/16/14 - €41.04
Market Cap
1.6B
Average Volume 10 Days
139.1K
EPS TTM
€2.11
Shares Outstanding
31.4M
EX-Date
05/4/15
P/E TM
24.5x
Dividend
€0.75
Dividend Yield
1.35%
Current Stock Chart for GERRESHEIMER AG (GXI)

Related News

No related news articles were found.

gerresheimer ag (GXI) Related Businessweek News

No Related Businessweek News Found

gerresheimer ag (GXI) Details

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates in three divisions: Plastics and Devices, Primary Packaging Glass, and Life Science Research. The Plastics and Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices. This division also provides containers for the delivery of tablets and powder, liquid dosage, ophthalmic and rhinological applications, and parenteral packaging applications. The Primary Packaging Glass division offers glass primary packaging for medicines and cosmetics, such as ampoules, cartridges, vials and syringe barrels, cartridges, syrup and dropper bottles, tablet jars, wide-neck jars and injections, and infusion and transfusion bottles; and flacons and pots for fragrances, deodorants, care and decorative cosmetics, etc., as well as specialty containers for spirits and food. The Life Science Research division produces reusable laboratory glassware for the research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders; and disposable laboratory products, including culture tubes, pipettes, chromatography vials, and other specialty laboratory glassware. Gerresheimer AG was founded in 1864 and is headquartered in Düsseldorf, Germany.

11,096 Employees
Last Reported Date: 02/11/15
Founded in 1864

gerresheimer ag (GXI) Top Compensated Officers

Chairman of the Management Board and Chief Ex...
Total Annual Compensation: €1.1M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €855.0K
Member of the Management Board
Total Annual Compensation: €805.0K
Compensation as of Fiscal Year 2014.

gerresheimer ag (GXI) Key Developments

Gerresheimer Launches an Eye Opener for Easy Use of Eye Droppers

Gerresheimer launched an Eye Opener for easy use of eye droppers. Suited for daily use, DropAid has circular aperture which fits perfectly onto eye drop bottle top and helps to open it with very little effort or pressure. When application aid is placed vertically on bottle neck with crescent part clipped onto open bottle, it can be rested firmly on side of eye so that correct number of drops can be given. DropAid is especially suitable for senior patients and children and is designed to fit System A Dropper Bottles for ophthalmic applications.

Gerresheimer AG Proposes Dividend for Financial Year 2014

At the Annual General Meeting on April 30, 2015, the Management Board and Supervisory Board of Gerresheimer AG will be jointly proposing a dividend of EUR 0.75 per share be paid out for financial year 2014 compared to prior year dividend of EUR 0.70 per share. This represents an increase of 7.1% against the prior-year dividend. The payout ratio amounts to 26% of adjusted net income after non-controlling interests.

Gerresheimer AG Reports Earnings Results for the Year Ended November 2014; Provides Earnings Guidance for the Year 2015 to 2018

Gerresheimer AG reported earnings results for the year ended November 2014. For the year, the company boosted revenues by 1.9% to EUR 1,290.0 million in financial year 2014. At constant exchange rates, purely organic growth in the company's Revenue was 3.7%. The company achieved this increase in revenues largely with plastic pharmaceutical packaging as well as products for the simple and safe administration of medicines, such as insulin pens, asthma inhalers and prefillable syringes. The company's adjusted EBITDA came to EUR 253.4 million in financial year 2014. Net income went up by 6.4% to EUR 72.9 million. Earnings per share rose 6.6% to EUR 2.11. In 2013, this figure stood at EUR 1.98. The company’s capital expenditure in financial year 2014 was EUR 126.6 million, representing 9.8% of revenues at constant exchange rates against EUR 119.1 million a year ago. The company anticipates organic revenue growth of 1% to 3% for financial year 2015. This corresponds to a revenue corridor of some EUR 1,300 million to EUR 1,330 million at constant exchange rates. The company expects an increase in adjusted EBITDA in a target corridor of EUR 255 million to EUR 265 million at constant exchange rates. Capital expenditure in financial year 2015 is forecast to represent around 9% to 10% of revenues at constant exchange rates. The company expects tax rate between 26% to 27%. The company is aiming for average annual organic revenue growth of 4% to 6% for the period from 2016 to 2018. For the adjusted EBITDA margin, the company has defined a target value of 21% for 2018.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GXI:GR €51.72 EUR +0.55

GXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Carclo PLC 132.25 GBp -4.75
Consort Medical PLC 843.00 GBp -17.00
Vitro SAB de CV $33.58 MXN +0.22
West Pharmaceutical Services Inc $56.89 USD -3.32
Zignago Vetro SpA €5.68 EUR 0.00
View Industry Companies
 

Industry Analysis

GXI

Industry Average

Valuation GXI Industry Range
Price/Earnings 21.5x
Price/Sales 1.1x
Price/Book 2.6x
Price/Cash Flow 21.5x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERRESHEIMER AG, please visit www.gerresheimer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.